Compare Direxion Daily Semiconductor Bear 3X Shares (SOXS) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily Semiconductor Bear 3X Shares vs Zoetis Inc — how do they compare? Direxion Daily Semiconductor Bear 3X Shares trades at $34.39 (market cap $1.96B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 15.4× Direxion Daily Semiconductor Bear 3X Shares's market cap, and Zoetis Inc pays a 2.9% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily Semiconductor Bear 3X Shares for 11 Days and Zoetis Inc for 70 Days on average.
| SOXS | ZTS | |
|---|---|---|
Market Cap | $1.96B | $30.20B |
Volume | 113,512,541 | 6,175,327 |
Sector | Leveraged / Inverse | Health |
52-Week High | $988.00 | $147.53 |
52-Week Low | $29.62 | $69.09 |
Typical Hold Time | 11 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, surged 10.23% to $33.78 amid semiconductor sector volatility. The technical outlook remains bearish with moving averages signaling continued downward pressure, while oscillators show neutral momentum. Recent news highlights SOXS benefiting from semiconductor sell-offs, though analysts caution it's suited only for short-term tactical trades due to extreme volatility and structural decay inherent in leveraged inverse ETFs.
As a leveraged inverse ETF, SOXS carries significant risks including daily rebalancing costs and time decay, making it unsuitable for long-term holdings. The fund thrives during semiconductor downturns but faces headwinds from persistent AI hardware demand. Investors should recognize this as a speculative trading instrument rather than a fundamental investment vehicle.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
